Biogen Inc. (BIIB) analyst actions
Rating and price-target actions on BIIB in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BIIB overview →
6 measured BIIB analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease | Press release | -0.40% | +0.80% | |
| FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease | Press release | -0.68% | -3.88% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biogen Inc. (BIIB) And Encourages Shareholders to Reach Out | Press release | -0.20% | -0.06% | |
| Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status | Press release | +1.59% | +1.48% | |
| Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy | Press release | -0.25% | -0.25% | |
| Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status | Press release | +1.65% | +2.77% |
Keep exploring
More BIIB: earnings → · SEC filings → · BIIB overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Orthofix Medical Inc. (OFIX) | 1,217 | +0.06% | 51% |
| IMMUNOMEDICS (IMMU) | 1,213 | -0.08% | 45% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 1,202 | -0.02% | 47% |
| Insulet Corporation (PODD) | 1,198 | +0.14% | 55% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.